How to reveal real AF of variant if duplicates can't be removed (such as in amplicon-seq)

Question

[CY]

As mentioned in the title, if duplicates removal can't be performed, such as in amplicon-seq, how do we recover real AF of variant? Won't PCR duplicates be a disruption?

[Pierre Lindenbaum]

Don't forget to follow up on your threads. If an answer was helpful, you should upvote it; if the answer resolved your question, you should mark it as accepted. You can accept more than one answer if they all work. If an answer was not really helpful or did not work, provide detailed feedback so others know not to use that answer.

• Any tools for predicting binding affinity between TCR and epitode?
• Method to detect genome doubling
• Can we get absolute abundance of TCR using TCR-Seq?
• Shannon vs Simpson for TCR diversity estimation
• Why did expression based subtypng of breast cancer gain much more acceptance than others
• Treat methylation as binary or continuous signal when detecting DMR?
• Is definition of differentially methylated region (DMR) biologically meaningful?
• Why NB distribution is preferred in RNA-Seq while normal distribution is preferred in microarray?
• Logit-normal distribution to model variation among biological replicates
• Identifying zygosity of somatic deletion
• In PCA on RNA-Seq data, what does Gaussian distribution refer to?
• Why can we still be able to continuously discover new cancer driver bioinformatically these days?
• non-reference allele didn't be called into vcf by HC
• Archieve of homologous nucleotide sequence across genome
• Library size normalization during CNV calling from genomically doubled tumor tissue
• Noisy CNV background in old FFPE sample
• Effect size in power analysis when dealing with Poisson based variant caller
• Why methylation sequencing requires much less sequencing depth than DNA-Seq?
• Mutated gene based pathway enrichment
• Why can't use t-test for differential expression (negative binomial distribution assumed)
• Multiple testing correction issue
• Is linearity maintained in linear regression of RNA-Seq?
• Why use LASSO / elastic net in survival regression?
• why PCA for RNA-Seq but tSNE for scRNA-seq?
• Can remote, but same type, tissue be used as RNA-Seq normal control for tumor study?
• Why NMF for mutation signature analysis
• Gene expression distribution (non-DE and DE)
• Would different enrichment tools result differently by defining pathway differently
• Any tools to estimate the relative abundance of immune cell in tumor
• Driver mutation vs biomarker vs recurrent mutation
• SciClone: Why cluster in non-CN neutral region considering it infers only on CN neutral region
• STAR-HT-Seq/featureCount got much more gene expression count than RSEM did
• Inconsistency of allele depth in BAM and VCF
• CBS in CNV calling
• How 2-channel sequencing chemistry (Next-Seq) distinguish "G" and 'no signal'
• one sample from pool shows low quality at the end, why?
• WGS coverage (depth) for CNV detection
• Reads aligning in unstranded RNA-Seq library
• what cause poly-G from NextSeq
• ExAC includes WES of phenotyped population
• Is DNA or RNA better to get somatic mutation profile for neoantigen estimation?
• Infer somatic mutations without normal control
• pipeline for neo-antigen identification
• Fragment size and insert size
• Why CNV calling using VarScan need two steps of fragments merging?
• Can phasing or pre-phase during basecall cause indel?
• Two confusion in bam format
• Why perfectly match (150M) records are not primary alignment in SAM
• A confusion regarding haplotype
• What kind of advantage does PEAR bring?
• Do multiple SNPs exist in same chromosome to be called allele?
• Will random hexamer priming introduce SNP / SNV detection bias?
• Detecting CNV can't cover aneuploidy situation
• STAR genomeLoad issue
• Distribution of somatic mutation
• Detecting variants at very low fractions from ctDNA
• Call variant from RNA-Seq data using Haplotypecaller